{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hepatitis-b/prescribing-information/hepatitis-b-vaccine/","result":{"pageContext":{"chapter":{"id":"8df28bde-0bc5-533e-a54b-507fd3ceee61","slug":"hepatitis-b-vaccine","fullItemName":"Hepatitis B vaccine","depth":2,"htmlHeader":"<!-- begin field 464b9cfe-203d-4ca9-9b19-d68e7acb71ab --><h2>What issues should I consider before prescribing hepatitis B vaccine?</h2><!-- end field 464b9cfe-203d-4ca9-9b19-d68e7acb71ab -->","summary":"","htmlStringContent":"<!-- begin item 1458a9ea-e26b-4ca7-80d5-33b123f48b6e --><!-- end item 1458a9ea-e26b-4ca7-80d5-33b123f48b6e -->","topic":{"id":"f75dcfde-3cb4-5059-94df-19d53a6c28e9","topicId":"4fc86266-0752-4667-994f-7f6fc7e46056","topicName":"Hepatitis B","slug":"hepatitis-b","lastRevised":"Last revised in November 2019","chapters":[{"id":"986057cd-07a1-565e-9c7a-d3b3dc88368d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2331f5c5-fb51-54d1-b722-946b4f34a693","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"653459fe-510a-5a1a-92dc-8197c598c85e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"12e8fb8c-9424-5f20-90e5-65e823f603c3","slug":"changes","fullItemName":"Changes"},{"id":"2299e2ba-3fb3-5f37-9c6b-63ec8dbbffd6","slug":"update","fullItemName":"Update"}]},{"id":"c14d3383-629b-5bd6-b6c0-318bbcf86fb2","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"58e5cd67-9ca7-5bfe-b2b6-bf4372ac895f","slug":"goals","fullItemName":"Goals"},{"id":"a1abbdfd-238b-55b7-8de2-09fd4ff6065b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fc44420e-13ab-526e-a0c7-ef2f93cce77b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b59d4642-5914-585b-82b1-6f7989cef100","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"af246587-2615-513e-aafc-3ea762d8aab7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bba17b9f-47f8-52cf-a8e7-111c1a5094a2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2c6fa000-50a2-5823-9acb-0bd808dc51e6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dfcb6ed4-783a-5fbc-9259-096762bb7c69","slug":"definition","fullItemName":"Definition"},{"id":"e06f78dc-080c-542f-b450-356db08c00a9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0c1d15cf-36ee-5c84-ad7c-e06836a161c0","slug":"transmission","fullItemName":"Transmission"},{"id":"939f1d6a-6b15-5c4f-91c8-9164e800cd87","slug":"people-at-high-risk-of-hepatitis-b","fullItemName":"People at high risk of hepatitis B"},{"id":"d452f04a-7d9d-5739-9cb9-f583eb136f3a","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"b3642d36-7175-548b-b6f0-d694e7397bd3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6acbd5e1-b0e6-527b-bad0-42c21a928d1e","slug":"when-to-test-for-hepatitis-b","fullItemName":"When to test for hepatitis B"},{"id":"706362c9-e255-511b-83b4-74b853c926c7","slug":"how-to-test-for-hepatitis-b","fullItemName":"How to test for hepatitis B"},{"id":"c0c1ae56-2316-56eb-ad65-4b85e982fc11","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"41c2681f-bf40-5b08-a518-32f2ab1206fb","fullItemName":"Management","slug":"management","subChapters":[{"id":"b2d949a2-a42f-5c0a-a955-414bac741bd3","slug":"prevention-of-infection-with-hepatitis-b","fullItemName":"Scenario: Prevention of infection with Hepatitis B"},{"id":"00ed825c-5927-50f5-940d-94d6b4001150","slug":"managing-hepatitis-b-infection","fullItemName":"Scenario: Managing hepatitis B infection"}]},{"id":"c7941282-a3b2-5716-b0cc-80cb243a7405","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8df28bde-0bc5-533e-a54b-507fd3ceee61","slug":"hepatitis-b-vaccine","fullItemName":"Hepatitis B vaccine"},{"id":"c7099851-c102-56f2-b063-021f3d00b880","slug":"analgesics","fullItemName":"Analgesics"},{"id":"6a9675fd-5496-5ca4-9a76-36ee6cc93a25","slug":"anti-emetics","fullItemName":"Anti-emetics"},{"id":"1576eb24-e96c-50e6-9976-05164be1127e","slug":"anti-pruritics","fullItemName":"Anti-pruritics"}]},{"id":"3c7651c1-b246-51db-85b3-e1b6713a47bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"548463b9-9c49-5154-bad9-fe10668804da","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8b3032fc-e20a-509b-b390-81cef2509ded","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5e0cdb38-e518-5a0c-9215-493c78f74377","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3e63144c-a0f3-5eb1-980d-a219e8a53633","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"94d851c4-3314-5a3d-801a-0a208e287514","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4df2edc1-d17c-57d1-a914-4100299c8f7d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cecf6c0b-d134-54cb-abef-c2ccab9effb6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c7941282-a3b2-5716-b0cc-80cb243a7405","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"fa3a1d5a-e81d-5aa5-b59e-a487a622461a","slug":"types-of-vaccine","fullItemName":"Types of vaccine","depth":3,"htmlHeader":"<!-- begin field 88622e7e-2bee-48f1-9e67-3835196cddd6 --><h3>What types of hepatitis B vaccine are available?</h3><!-- end field 88622e7e-2bee-48f1-9e67-3835196cddd6 -->","summary":"","htmlStringContent":"<!-- begin item 3ca1f759-804c-41aa-9546-13b72aab8de6 --><!-- begin field b985101e-9f27-43ca-b932-698963dd88df --><ul><li>There are several hepatitis B vaccines licensed for use in the UK, all of which are inactivated:<ul><li>Engerix B<sup>®</sup>.</li><li>Fendrix<sup>®</sup>.</li><li>HBvaxPRO<sup>®</sup>.</li></ul></li><li>Two combined hepatitis A and B vaccines, Twinrix<sup>® </sup>and Ambirix<sup>®</sup>, are also available.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field b985101e-9f27-43ca-b932-698963dd88df --><!-- end item 3ca1f759-804c-41aa-9546-13b72aab8de6 -->","subChapters":[]},{"id":"7a092d50-1634-5a31-bace-318f3e91eba7","slug":"immunization-schedule","fullItemName":"Immunization schedule","depth":3,"htmlHeader":"<!-- begin field 39634d36-4f74-42e8-b3e1-90bf4ddbeab5 --><h3>What is the immunization schedule for the hepatitis B vaccine?</h3><!-- end field 39634d36-4f74-42e8-b3e1-90bf4ddbeab5 -->","summary":"","htmlStringContent":"<!-- begin item 39558279-5d4b-4d16-b918-01c8202289f4 --><!-- begin field eb6e7d61-babc-4f14-a774-2a0b7b53241b --><ul><li><strong>Different hepatitis B vaccines, doses, and primary dosing schedules are recommended depending on the person's age and whether they are receiving haemodialysis.</strong> For further information, consult the <a data-hyperlink-id=\"2bb0ae01-61df-41a6-a2fc-aaff01345270\" href=\"https://bnf.nice.org.uk/drug/hepatitis-b-vaccine.html#directionsForAdministration\">BNF</a>.</li><li><strong>For most adult and childhood risk groups, an accelerated schedule should be used</strong>, with vaccine usually given at zero, one and two months. An alternative schedule (usually) at zero, one and six months should only be used where rapid protection is not required and there is a high likelihood of compliance.<ul><li>For information on vaccination schedule for babies born to women with hepatitis B, see Public Health England's information leaflet for Information for GPs and practice nurses <a data-hyperlink-id=\"cfb20328-f64a-4a01-a916-ab07012c8bef\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/736036/HepB_babies_aide_memoire_.pdf\">Hepatitis B vaccine for at risk infants</a>.</li></ul></li><li><strong>People in certain risk groups (occupationally exposed, people with renal failure), should have their antibody titres checked one to four months after the completion of a primary course of vaccine. In all other people, antibody testing is not considered necessary.</strong><ul><li>It is preferable to achieve anti-HBs levels above 100mIU/ml, although levels of 10mIU/ml or more are generally accepted to protect against infection.</li><li>People found to have anti-HBs levels of 10 to 100mIU/ml should receive one additional dose of vaccine.</li><li>In immunocompetent individuals, once a response has been established, further assessment of antibody levels is not indicated.</li><li>In non-responders (people with antibody levels below 10mIU/ml), serology should be checked for past or current hepatitis B infection. A repeat course of vaccine is recommended, followed by retesting of antibody levels one to four months after the second course. If there is still an inadequate response, these people will require immunoglobulin for protection if exposed to hepatitis B.</li><li>For people with chronic renal failure receiving haemodialysis, antibody levels should be monitored annually, and if they fall below 10mIU/ml, a booster dose of vaccine should be given if the person has previously responded. A booster should also be offered if travel to a high risk country is planned and it is more than one year since the last booster.</li></ul></li><li><strong>Longer than recommended intervals between doses do not appear to reduce the final antibody level or efficacy. </strong>There is no need to repeat doses if the vaccination course is interrupted.</li><li><strong>Booster doses after the primary course are not routinely required for healthy, immunocompetent adults. However, a booster should be administered following a significant exposure.</strong></li><li><strong>Note:</strong> <strong>In 2017, Public Health England released temporary recommendations in response to a global shortage of monovalent hepatitis B vaccine</strong>, in order to preserve vaccine stocks for groups with highest need and most likely to benefit. Please consult PHE's <a data-hyperlink-id=\"ec460d5d-1945-4d89-9ba9-aafe0168e974\" href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/631145/Hepb_vaccine_temporary_recommendations_adults_and_children.pdf\">guidance</a> where vaccine supply issues have been noted.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">NaTHNac, 2019</a>]</p><!-- end field eb6e7d61-babc-4f14-a774-2a0b7b53241b --><!-- end item 39558279-5d4b-4d16-b918-01c8202289f4 -->","subChapters":[]},{"id":"ac7a12f8-afc3-5093-87f1-7b07f6cc1e66","slug":"people-with-hiv","fullItemName":"People with HIV","depth":3,"htmlHeader":"<!-- begin field 6275106e-7fe2-4d08-b370-1b4196d3470c --><h3>What hepatitis B vaccination schedule should be used for people with HIV?</h3><!-- end field 6275106e-7fe2-4d08-b370-1b4196d3470c -->","summary":"","htmlStringContent":"<!-- begin item 9b8a6441-2cd4-4505-b80c-df51f980c42d --><!-- begin field ddefbd87-45eb-4b4a-8dd1-3cf9e03a2889 --><ul><li><strong>Hepatitis B vaccine should be offered to people with HIV who are at risk of infection, as they are more likely to contract hepatitis B and also to develop chronic infection.</strong><ul><li>Four doses at 0, 1, 2, and 6 months are usually recommended.</li><li>If an unadjuvanted vaccine is being used (Engerix®, HBvaxPRO®) a high dose (40 µg) is recommended. If the adjuvanted vaccine (Fendrix®) is being used, the standard (20 µg) dose can be used.</li><li>An ultra-rapid vaccination course (three standard-doses given over 3 weeks) should only be considered in people with CD4 cell counts >500 cells/μL, where rapid protection is necessary, and/or where compliance with a more protracted course is considered unlikely. High dose vaccine is not recommended in these circumstances due to a lack of safety data. </li></ul></li><li><strong>Measure antibodies to hepatitis B surface antigen (HBsAb) 4–8 weeks after completion of the vaccination schedule.</strong><ul><li>If HBsAb is less than 10 IU/L, offer the person three further vaccine doses (as described above) at monthly intervals.<ul><li>Depending on the level of risk, re-vaccination may be delayed until the viral load is suppressed on ART and the CD4 cell count has increased >350 cells/μL.</li><li>Retesting for HBsAb is recommended 4–8 weeks after the final dose of vaccine.</li></ul></li><li>If HBsAb is greater than 10 IU/L but less than 100 IU/L, offer the person one additional dose of vaccine.<ul><li>Check the response 4–8 weeks later.</li></ul></li></ul></li><li><strong>Following successful immunization (HBsAb >10 IU/L after completion of a full vaccine course) the person should be offered regular HBsAb testing </strong>(using clinical judgement to determine frequency).<ul><li>People with initial HBsAb levels >100 IU/L, CD4 cell counts >350 cells/μL, and viral load suppression on ART should be retested at least every 2–4 years</li><li>Other people should receive HBsAb testing on an annual basis.</li><li>A booster dose of vaccine should be offered if HBsAb levels have declined to less than 10 IU/L.</li></ul></li><li><strong>Further boosters are required following a high-risk exposure to an HBsAg-positive source.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">BHIVA, 2015</a>]</p><!-- end field ddefbd87-45eb-4b4a-8dd1-3cf9e03a2889 --><!-- end item 9b8a6441-2cd4-4505-b80c-df51f980c42d -->","subChapters":[]},{"id":"d79956d1-7062-57c6-8b4f-cf5faa02b461","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field f358785f-f4e6-4f24-be2f-e43ec58ea74d --><h3>When is the hepatitis B vaccine contraindicated?</h3><!-- end field f358785f-f4e6-4f24-be2f-e43ec58ea74d -->","summary":"","htmlStringContent":"<!-- begin item 4e95ec39-68f5-4948-bbd8-b89242fe819a --><!-- begin field ab2b3eeb-33be-420d-834a-613c0d510ac8 --><ul><li>Do not give hepatitis B vaccine to people with:<ul><li>Current severe febrile illness.</li><li>A confirmed anaphylactic reaction to a previous dose of hepatitis B vaccine.</li><li>A confirmed anaphylactic reaction to a component of hepatitis B vaccine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">Joint Formulary Committee, 2019</a>] </p><!-- end field ab2b3eeb-33be-420d-834a-613c0d510ac8 --><!-- end item 4e95ec39-68f5-4948-bbd8-b89242fe819a -->","subChapters":[]},{"id":"af248f74-6291-5d7d-882d-412b5b48002b","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 9543af9a-6f19-4886-9ad3-019699d1c4d2 --><h3>Can the hepatitis B vaccine be used during pregnancy and breastfeeding?</h3><!-- end field 9543af9a-6f19-4886-9ad3-019699d1c4d2 -->","summary":"","htmlStringContent":"<!-- begin item 2d3e8adc-f442-44ae-a9da-e2d6bd9f44f8 --><!-- begin field 9130d8a2-fbe7-40f1-8e7a-05018bc1b797 --><ul><li>Hepatitis B vaccines can be used during pregnancy and breastfeeding, if clinically indicated, for women at high-risk of infection, as hepatitis B in a pregnant woman may result in severe disease for the mother and chronic infection of the infant after birth [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2017</a>].<ul><li>The available evidence does not indicate any risk associated with vaccinating pregnant women, or those who are breastfeeding, with inactivated viral vaccines in general [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">Plotkin et al, 2004</a>] or with hepatitis B vaccines specifically [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">UKTIS, 2016</a>].</li></ul></li></ul><!-- end field 9130d8a2-fbe7-40f1-8e7a-05018bc1b797 --><!-- end item 2d3e8adc-f442-44ae-a9da-e2d6bd9f44f8 -->","subChapters":[]},{"id":"acec744d-d293-503f-871b-e2ba582f7f50","slug":"administration","fullItemName":"Administration","depth":3,"htmlHeader":"<!-- begin field 909e6780-69ac-439c-ac5c-f322a4679dd1 --><h3>How should I administer the hepatitis B vaccine?</h3><!-- end field 909e6780-69ac-439c-ac5c-f322a4679dd1 -->","summary":"","htmlStringContent":"<!-- begin item a2c2e7c5-426b-465e-9ea2-9cec7c3b11f9 --><!-- begin field 07c82b4a-e9de-4658-a537-b68f67885330 --><ul><li>Obtain written or verbal consent at the time of vaccination.</li><li>Check that the vaccine is correct and has not expired. Only clean the site of application with soap and water if it is visibly dirty.</li><li>For adults and children older than 1 year of age, administer the vaccine by intramuscular injection into the deltoid muscle.</li><li>For children younger than 1 year of age, administer the vaccine by intramuscular injection into the anterolateral aspect of the thigh.</li><li>If the person has a bleeding disorder, use the deep subcutaneous route, to reduce the risk of bleeding.</li><li>Record the site of administration. If an additional vaccine is required on the same day, use separate limbs if possible, or inject at sites at least 2.5 cm apart in the same limb.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2013a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2013b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">PHE, 2013c</a>]</p><!-- end field 07c82b4a-e9de-4658-a537-b68f67885330 --><!-- end item a2c2e7c5-426b-465e-9ea2-9cec7c3b11f9 -->","subChapters":[]},{"id":"4dbc5b8a-c3c1-556d-b57d-0483aaa19093","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 74e999c2-7d4e-47ec-b291-cc10eaeef9b5 --><h3>What are the adverse effects of the hepatitis B vaccine?</h3><!-- end field 74e999c2-7d4e-47ec-b291-cc10eaeef9b5 -->","summary":"","htmlStringContent":"<!-- begin item 819eb5da-0bde-45c5-8a68-87d9ba6a5c94 --><!-- begin field bea1e353-6b8c-4ee3-b618-e61b79578e81 --><ul><li>Hepatitis B vaccine is generally well tolerated. The most common adverse reactions are soreness and redness at the injection site.</li><li>Other reactions that have been reported (but may not be causally related) include fever, rash, malaise, an influenza-like syndrome, arthritis, arthralgia, myalgia, and abnormal liver function tests.</li><li>Suspected serious neurological reactions (such as Guillain–Barré syndrome and demyelinating disease) have been reported, although these are very rare and a causal relationship with hepatitis B vaccine has not been established.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hepatitis-b/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field bea1e353-6b8c-4ee3-b618-e61b79578e81 --><!-- end item 819eb5da-0bde-45c5-8a68-87d9ba6a5c94 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}